Dosing for Kenacort A10 in PIP Joint Injection
For a proximal interphalangeal (PIP) joint injection, use 20 mg of Kenacort A10 (triamcinolone acetonide). This is the standard dose for small finger joints based on FDA labeling and supported by clinical research 1, 2.
Specific Dosing Recommendations
The FDA-approved dosing for Kenacort A10 in small joints is clear:
- PIP joints: 20 mg per injection
- MCP joints: 20 mg per injection
- Wrist joints: 40 mg per injection
- Larger joints: 5-15 mg depending on size 1
This dosing is directly supported by clinical research demonstrating that 20 mg triamcinolone acetonide is effective for PIP joint arthritis in rheumatoid arthritis patients, with significant improvements in pain, tenderness, and swelling 2.
Key Technical Points
Volume and concentration: Kenacort A10 contains 10 mg/mL, so you'll need to draw up 2 mL for a 20 mg dose in a PIP joint 1.
Injection technique considerations:
- Use strict aseptic technique (mandatory) 3, 1
- Shake the vial before use to ensure uniform suspension 1
- Inspect for clumping/agglomeration - discard if present 1
- Inject without delay after drawing up to prevent settling 1
- Consider ultrasound guidance for improved accuracy, particularly in small joints 3, 2
- A tuberculin syringe with 23-25 gauge needle is preferable for accuracy 1
Important Clinical Caveats
Patient counseling requirements per EULAR guidelines 3:
- Obtain informed consent and document it
- Offer local anesthetic (explain pros/cons)
- For diabetic patients: warn about transient hyperglycemia days 1-3 post-injection and advise glucose monitoring
- Instruct to avoid overuse of the joint for 24 hours, but discourage complete immobilization
Reinjection considerations: If the initial injection fails, the decision to reinject should consider the response to the first injection. While there's no absolute evidence-based limit, the general accepted practice is to avoid more than 3-4 glucocorticoid injections in the same joint per year 3.
Special consideration for hand OA: EULAR guidelines note that intra-articular glucocorticoids should not generally be used in hand osteoarthritis, but may be considered in patients with painful interphalangeal joints 3. This suggests the indication matters - this approach is more established for inflammatory arthritis than osteoarthritis.